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Abstract
Introduction: Current hormonal adjuvant therapies for breast cancer including tamoxifen treatment and estrogen
depletion are overall tumoristatic and are severely limited by the frequent recurrence of the tumors. Regardless of
the resistance mechanism, development and progression of the resistant tumors requires the persistence of a basal
level of cycling cells during the treatment for which the underlying causes are unclear.
Methods: In estrogen-sensitive breast cancer cells the effects of hormone depletion and treatment with estrogen,
tamoxifen, all-trans retinoic acid (ATRA), fulvestrant, estrogen receptor a (ER) siRNA or retinoic acid receptor a
(RARa) siRNA were studied by examining cell growth and cycling, apoptosis, various mRNA and protein expression
levels, mRNA profiles and known chromatin associations of RAR. RARa subtype expression was also examined in
breast cancer cell lines and tumors by competitive PCR.
Results: Basal proliferation persisted in estrogen-sensitive breast cancer cells grown in hormone depleted
conditioned media without or with 4-hydroxytamoxifen (OH-Tam). Downregulating ER using either siRNA or
fulvestrant inhibited basal proliferation by promoting cell cycle arrest, without enrichment for ErbB2/3+
overexpressing cells. The basal expression of RARa1, the only RARa isoform that was expressed in breast cancer
cell lines and in most breast tumors, was supported by apo-ER but was unaffected by OH-Tam; RAR-b and -g were
not regulated by apo-ER. Depleting basal RARa1 reproduced the antiproliferative effect of depleting ER whereas its
restoration in the ER depleted cells partially rescued the basal cycling. The overlapping tamoxifen-insensitive gene
regulation by apo-ER and apo-RARa1 comprised activation of mainly genes promoting cell cycle and mitosis and
suppression of genes involved in growth inhibition; these target genes were generally insensitive to ATRA but
were enriched in RAR binding sites in associated chromatin regions.
Conclusions: In hormone-sensitive breast cancer, ER can support a basal fraction of S-phase cells (i) without
obvious association with ErbB2/3 expression, (ii) by mechanisms unaffected by hormone depletion or OH-Tam and
(iii) through maintenance of the basal expression of apo-RARa1 to regulate a set of ATRA-insensitive genes. Since
isoform 1 of RARa is genetically redundant, its targeted inactivation or downregulation should be further
investigated as a potential means of enhancing hormonal adjuvant therapy.
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Most breast tumors in both premenopausal and postme-
nopausal women express estrogen receptor type alpha
(ER). Tamoxifen is a Selective Estrogen Receptor Modu-
lator (SERM) widely used for adjuvant therapy in the
treatment of ER+ breast cancer. In the hormone-sensi-
tive tumors, tamoxifen acts as a partial antagonist,
impairing ER function by competing with estrogen for
binding to the receptor [1]; however, more than three
years of tamoxifen treatment only results in approxi-
mately 50% reduction in the incidence of invasive breast
cancer in women at high risk, whereas about a third of
ER+ breast tumors are intrinsically resistant to tamoxi-
fen [2,3].
Third generation aromatase inhibitors (AI) present a
valuable alternative to tamoxifen adjuvant therapy in
postmenopausal women with ER+ breast cancer [4-6].
Aromatase activity is essential for catalyzing the conver-
sion to estrogen of steroid precursors in peripheral tis-
sues, the major source of estrogen production in
postmenopausal women. Upon treatment with AI, aro-
matase activity is reduced by at least 96% and circulat-
ing estrogen is virtually absent, inhibiting hormone-
dependent tumor growth [7]. In spite of the sensitivity
of tamoxifen-resistant tumors to AI, breast tumors also
acquire resistance to AI after long term treatment,
resulting in disease recurrence and aggressive tumor
growth [8,9]. Clinical trials are underway to assess the
possibility of delaying the onset of resistance by admin-
istering AI for two to three years following two to three
years of tamoxifen treatment [10,11]. The mechanistic
basis underlying breast tumor resistance to either hor-
mone depletion or to tamoxifen is still inadequately
understood. In the vast majority of cases, resistance
must occur through hormone-independent ER signaling
events [12,13]. Accordingly, Selective Estrogen Receptor
Downregulators (SERDs, for example, Faslodex) have
been found to be effective inhibitors of ER+ breast
tumor growth but their utility is limited to their use as
second or third line therapeutics in postmenopausal
women with metastatic disease due to their broader
impact on physiological ER signaling pathways in nor-
mal tissues [14,15]. Therefore, it is imperative to con-
tinue to identify critical downstream events of ER
signaling in breast cancer.
Breast cancer therapy trials have also been designed to
explore the effect of retinoid compounds either alone or
in combination with tamoxifen [16]. In in vitro and
pre-clinical models of breast cancer using MCF-7 cell
xenografts, all-trans- retinoic acid (ATRA) alone or in
combination with tamoxifen induced cell cycle arrest
and apoptosis, leading to tumor regression through acti-
vation of multiple signal transduction pathways [17-19].
Synergistic anti-tumor effects have been noted in vitro
for the combination of retinoid and tamoxifen and mul-
tiple molecular mechanisms for the ligand effects have
been reported [20,21]. However, toxicity issues due to
ATRA treatment was a challenge in patients with
advanced breast cancer during phaseI/II clinical trials
[22]. Fenretinide, a synthetic amide of retinoic acid, has
a better toxicological profile acting on both ER+ and
ER- breast tumors principally by inducing apoptosis by
both retinoic acid receptor (RAR) -dependent and -inde-
pendent mechanisms; this drug showed a modest che-
mopreventive effect only in younger premenopausal
women [23].
Hormonal adjuvant therapy of breast cancer is overall
tumoristatic with cell death balancing a basal level of
cell proliferation [24]. From a fundamental mechanistic
standpoint, for resistance to develop in the long term
during either hormone depletion or tamoxifen adjuvant
therapy, the latent tumors must sustain a basal level of
cell cycling to enable the generation and/or progression
of genetic or epigenetic changes [25] leading to resis-
tance. It is the premise of this study that understanding
the mechanisms that support the persistence of a small
fraction of cells in S-phase throughout the course of
hormonal adjuvant therapy in breast cancer will shed
light on this critical precondition for the eventual devel-
opment of resistance to the treatments. Since estrogen-
independent ER signaling has been implicated in the
development of resistance to adjuvant therapy, it was
the goal of this study to examine the relationship
between hormone-independent actions of ER and the
basal cycling state of estrogen deprived breast cancer
cells. Further, the ER-RAR axis has only been investi-
gated in the context of ligand-dependent effects [26]; it
was therefore of additional interest to explore a possible
interplay between the apo- forms of ER and RAR and
its impact on basal proliferation, that is, under condi-
tions of hormone depletion or tamoxifen antagonism.
Estrogen-sensitive breast cancer cell lines (MCF-7,
T 4 7Da n dZ R - 7 5 - 1 )h a v ep r o v e nt ob ee x c e p t i o n a l l y
reliable predictive models both in vitro and in vivo for
clinical drug response and the development of clinical
drug resistance in breast cancer [27-30]. We have
observed that the expected basal proliferating state of
hormone-depleted or tamoxifen treated breast cancer
cells may be reproduced in vitro in established cell lines
for an indefinite period by avoiding the common prac-
tice of intermittently replenishing the culture media,
thus avoiding depletion of autocrine growth factors. We,
therefore, used in vitro models to investigate the poten-
tial impact of hormone-independent actions of ER on
the survival or proliferation of hormone-sensitive breast
cancer cells and the related mechanisms under
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is, estrogen-depletion and tamoxifen treatment.
Materials and methods
Chemicals and reagents
Dulbecco’s minimum essential medium (DMEM), gluta-
mine and penicillin/streptomycin/glutamine stock mix
were purchased from Life Technologies, Inc. (Carlsbad,
CA, USA). Fetal bovine serum (FBS) and charcoal-
stripped FBS were from Invitrogen (Carlsbad, CA, USA).
Fugene 6 and Dharmafect 1 were from Roche Diagnos-
tics (Indianapolis, IN, USA) and Dharmacon (Thermo
Scientific Dharmacon, Inc., Lafayette, CO, USA), respec-
tively. ERa (J-003401-12), RARa (J-003437-07) and con-
trol (D-001810-02) small interfering RNA (siRNA) were
purchased from Dharmacon (Thermo Scientific Dhar-
macon, Inc.). Affinity purified rabbit and mouse antibo-
dies to human ERa (sc-543), RARa (sc-551), RARb
(sc-552), RARg (sc-550) and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH; sc-47724) were from Santa
Cruz Biotechnologies (Santa Cruz, CA, USA). Peroxi-
dase-conjugated secondary antibody was from Vector
Laboratories (Burlingame, CA, USA). For standard PCR,
HotStart Taq Plus DNA Polymerase was used (Qiagen,
Germantown, MD, USA). Reagents for real time PCR,
primers and TaqMan probes were purchased from
Applied Biosystems (Branchburg, NJ, USA). PI/RNase
staining buffer was from BD Pharmigen (San Diego, CA,
USA). The Guava Nexin Reagent was purchased from
Guava Technologies (Guava Technologies, Inc., Hay-
ward, CA, USA). The protease inhibitor cocktail kit was
obtained from Pierce Biotechnology (Thermo Scientific,
Rockford, IL, USA). 17b-estradiol (E2), 4-hydroxytamox-
ifen (OH-Tam), all-trans-Retinoic acid (ATRA) and ful-
vestrant were purchased from Sigma Aldrich (Saint
Louis, MO USA). ATRA stock solution (5 mmol/L) was
made in a mixture of 50% ethanol and 50% DMSO
(Fisher Chemical, Fair Lawn, NJ, USA). First strand
cDNA from human peripheral blood leukocytes (PBL),
thymus and spleen were obtained from Biochain Insti-
tute (Biochain Institute Inc., Hayward, CA, USA). Total
RNA from normal human breast and human breast
tumors were obtained from Biochain Institute Institute
and Clonetech (Clonetech Laboratories Inc., Mountain
View, CA, USA).
Cell culture and treatment with fulvestrant or ATRA
MCF-7 and T47 D (American Type Culture Collection)
cells were cultured in DMEM supplemented with FBS
(10%), penicillin (100 unit/ml), streptomycin (100 μg/
ml) and L-glutamine (2 mM). ZR-75-1 (American Type
Culture Collection) cells were cultured in RPMI 1640
supplemented with FBS (10%), penicillin (100 unit/ml),
streptomycin (100 μg/ml) and L-glutamine (2 mM).
Hormone depleted cells were grown in low glucose phe-
nol-red free media supplemented with 5% charcoal-
s t r i p p e dF B S( v / v )a n dL - g l u t a m i n e( 2m M )f o r
48 hours before the experiments. Hormone-depleted
MCF-7 cells were grown to 60 to 70% confluency in six-
well plates and treated with vehicle or ATRA (1 μM) for
24 hours. After 24 hours, the cells were harvested for
total RNA isolation and mRNA profiling. Hormone-
depleted MCF-7 cells were grown to 30 to 40% con-
fluency in six-well plates and treated with vehicle or
fulvestrant (100 nM) for up to 4 days. After 72 hours to
96 hours, the cells were harvested for isolation of total
RNA and protein.
Transfection and gene silencing
Cells were plated at 20% confluence in low glucose
phenol red free medium supplemented with 5% char-
coal stripped FBS and glutamine 24 hours to 48 hours
prior to transfection. Treatment with vehicle (ethanol),
E2 ( 1n M )o rO H - T a m( 1 0 0n M )w a sb e g u na na d d i -
tional 24 hours later. Cells were transfected with con-
trol siRNA, ERa siRNA or RARa siRNA (100 pmol/
mL) in 24-well microplates or 25 cm
2 flasks using 2 μl
and 12.5 μl of Dharmafect 1 (Thermo Scientific Dhar-
macon Inc.), respectively, according to the vendor’s
protocol. The cell culture medium was not replenished
for the duration of the experiment. In the RARa1r e s -
cue experiments, 2 × 10
6 cells were co-transfected
with 2 μg of either the vector plasmid or RARa1
expression plasmid and with control siRNA or ERa
siRNA by nucleofection using the Kit V Amaxa
Nucleofection System (Amaxa Biosystems, Allendale,
NJ, USA) according to the vendor’s instructions. In the
RARa1 rescue of fulvestrant- treated cells and RARa1
overexpression experiments, 2 μgR A R a1 expression
plasmid was introduced at a cell density of 2.5 × 10
5
cells per well in six-well plates using Fugene 6 accord-
ing to the manufacturer’sp r o t o c o l .
Cell growth assay
Cells were seeded in 24-well microplates at 20% conflu-
ence in phenol-red free media supplemented with 5%
charcoal-stripped FBS (v/v) and incubated at 37°C with
5% CO2 for 24 h. Cells were transfected with either con-
trol siRNA or siRNA targeting ERa using Dharmafect 1.
Twenty-four hours after transfection the media was
replaced with fresh phenol-red free media supplemented
with 5% charcoal-stripped FBS (v/v) and the cells were
treated with vehicle (ethanol), E2 (1 nM) or OH-Tam
(100 nM) for the following five days; the culture media
was not changed during this period but E2 and OH-
Tam were replenished every 48 h. Viable cell counts
were monitored using the trypan blue dye exclusion
assay at intervals of 24 h.
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Cells were trypsinized and harvested in phenol red free
medium supplemented with charcoal stripped FBS. Cells
(1 × 10
6) were washed and resuspended in 500 μlP B S .
The cells were fixed by adding 500 μl 100% ice cold
ethanol, drop-wise with agitation and incubated on ice
for 20 minutes. The cells were sedimented by brief cen-
trifugation at 200 xg for five minutes and the excess
ethanol decanted. After the remaining ethanol was dried
off, the cells were resuspended in 500 μlo fP I / R N a s e
solution. The cells were incubated in the dark at room
temperature for 20 minutes and the cell cycle distribu-
tion determined by flow cytometric analysis using a
FACSCalibur cell analyzer (BD Biosciences, San Jose,
CA, USA). The data were acquired with BD CellQuest
Pro software and analyzed using ModFit LT software.
Apoptosis assay
Early stage apoptosis of cells was measured by Guava
Nexin analysis using the Guava Nexin Reagent staining
kit according to the manufacturer’s instructions. Briefly,
8×1 0
4 cells were incubated for 20 minutes at room
temperature with the Guava Nexin Reagent and 2,000
cells per sample were analyzed using the Guava System.
Western blot
Cells were harvested by trypsinization, lysed in a high salt-
detergent buffer (400 nM NaCl; 10 nM Tris, pH 8.0;
1 mM EDTA; 1 mM EGTA; b-mercaptoethanol; and 0.1%
Triton x-100) containing a protease inhibitor cocktail kit
and incubated on ice for 30 minutes. Cell lysates were
heated to 95°C for five minutes. Protein samples (10 to
20 μg) were resolved by electrophoresis on 8% sodium
dodecylsulfate-polyacrylamide gels and electrophoretically
transferred to PVDF membranes (Millipore Corporation,
Bedford, MA, USA). The blots were probed with the
appropriate primary antibody and the appropriate horse-
radish peroxidase conjugated secondary antibody and the
protein bands visualized using enhanced chemilumines-
cence as described [31]. The chemiluminescent signals
were quantified using the FluorChem HD2 imaging sys-
tem (Alpha Innotech/Cell Biosciences, Inc., Santa Clara,
CA, USA) and normalized to GAPDH.
RNA isolation, reverse transcription PCR and Real time
PCR
Total RNA from cells was isolated using the RNeasy
mini kit (Qiagen, Georgetown, MD, USA). Reverse tran-
scription PCR reactions were performed using 500 ng of
total RNA and the high capacity complementary DNA
Archive kit (Applied Biosystems) according to the ven-
dor’s protocol. cDNAs of RARa1a n dR A R a2w e r e
amplified by competitive PCR. The upstream and down-
stream primers used for amplification of RARa1a n d
RARa2w e r ea sf o l l o w s :R A R a1, 5’-GCCAGG-
CGCTCTGACCACTC-3’ and 5’-AGCCCTTGCAGCC-
CTCACAG-3’;R A R a2, 5’-ACTCCGCTTTGGAATGG
CTCAAAC-3’ and 5’-AGCCCTTGCAGCCCTCACAG-
3’. The cDNA for the house keeping gene glyceralde-
hyde-3- phosphate dehydrogenase (GAPDH) was
amplified and the primer sequences used were as
follows: 5’-TGGTCACCAGGGCTGCTTTT-3’ and
5’-GGTGAAGACGCCAGTGGACT-3’. The cycling
parameters were: 95°C for 15 minutes; 94°C for 30 sec;
60°C for 30 sec; 72°C for 30 sec and 72°C for 10 min-
utes. RARa1a n dR A R a2 cDNAs were amplified in the
same reaction, yielding products of 222 bp and 182 bp,
respectively. PCR products were separated in ethidium
bromide-stained 2% agarose gels by electrophoresis.
cDNA was also measured by quantitative real time
PCR in the 7500 StepOne Plus Real time PCR System
(Applied Biosystems). Primers and TaqMan probes for
the human ERa, CCNA, CDKN1, ERBB2, ERBB3,
MUC20, LYPD1, RARa and GAPDH genes were
obtained from the Applied Biosystems inventory. All
samples were measured in triplicate and normalized to
GAPDH values.
mRNA profiling
The Affymetrix chips were purchased from Affymetrix
(Santa Clara, CA, USA) DNA microarray analysis using
Affymetrix was performed as a full service global gene
expression study at the transcriptional profiling core
facility of the Cancer Institute of New Jersey. Total
RNA samples were used to generate labeled cRNAs,
which were hybridized to human U133 Plus2.0 Affyme-
trix microarrays. The expression data were analysed
initially using Affymetrix GeneChip Operating Software
to create CEL files. The CEL files were imported into
the Bioconductor program affylmGUI [32]. The probe
set level intensities were quantified and normalized
using robust multiarray averaging and quantile normali-
zation. Differential expression between treatments was
determined using the limma linear modeling method,
and the significance of differences was ranked by the
moderated t-statistic. The values for signal intensities
were corrected for siRNA transfection efficiencies deter-
mined using a Green Fluorescent Protein (GFP) reporter
expression plasmid. To identify genes differentially
expressed under the different treatments, the fold-
changes were calculated by dividing the average signal
of the treatment by the control, and genes with a fold-
c h a n g eg r e a t e ro rl e s s e rt h a nag i v e nt h r e s h o l dw e r e
chosen. The advantage of this approach is that rejection
of many false negatives is avoided, compared to requir-
ing a statistically significant difference in expression, but
has the potential drawback of including false positives.
When we limited the genes in Tables 1 and 2 to those
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0.05 level by the linear modeling method, 25/54 genes
in Table 1 and 24/68 genes in Table 2 were retained. In
the reduced sets of genes, similar percentages of genes
showed RARa peaks as in the larger gene set, confirm-
ing the generality of our result. The Affymetrix data are
deposited in GEO (Accession number: [GEO:
GSE26298]).
Statistical analyses
Experimental values are presented as mean ± standard
deviation (s.d.). The statistical significance of differences
(P-value) between values being compared was deter-
mined using analysis of variance. In all cases, the differ-
ences noted in the text are reflected by a P-value of
<0.001.
Results
In estrogen-sensitive MCF-7 cells basal proliferation is
supported by ER in the absence of hormone
In the following studies, in experiments in which MCF-7
cells were depleted of hormone, the virtual absence of
hormone was confirmed in two ways. First, the effect of
OH-Tam on the expression of the classical E2 target
gene, EGR3 (Early Growth Response 3 gene) was exam-
ined as a functional test. The expression of EGR3
mRNA is exquisitely sensitive to upregulation by E2, in a
manner that is completely antagonized by OH-Tam. In
the hormone depleted cells, the inability of OH-Tam to
further decrease EGR3 mRNA indicated the virtual
absence of hormone (Figure 1A). Second, the effect of
E2 on the relative phosphorylation level at ser
118 of ER
was examined. The binding of E2 strongly induces
Table 1 Tamoxifen Insensitive genes supported by the Apo-ER -> Apo-RARa Axis
Gene ATRA
effect
RAR
a binding
<10 kb
Fold
change siER
Fold change
siRARa1
Gene ATRA
effect
RAR
a binding
<10 kb
Fold
change siER
Fold change
siRARa1
LGALS1 ↓ - 0.31 0.46 CASC5 - - 0.47 0.51
METTL7A ↓ - 0.37 0.53 BIRC5 - - 0.53 0.48
CDKN3 ↓ - 0.44 0.60 PTTG1 - - 0.57 0.54
XK ↓ - 0.46 0.54 PLK4 - - 0.56 0.49
GHR ↓ - 0.41 0.57 CENPA - - 0.58 0.56
YPEL1 ↓ - 0.58 0.54 TMSB15A - - 0.42 0.41
SHANK2 ↑ ++ 0.58 0.57 C5 - - 0.38 0.48
ENY2 - ++ 0.54 0.45 CDC2 - - 0.56 0.59
ONECUT2 - ++ 0.50 0.58 CCNA2 - - 0.59 0.52
HIST1H4C - ++ 0.21 0.31 LOC150759 - - 0.49 0.59
NCAPH - ++ 0.47 0.53 NCAPG - - 0.50 0.51
CENPN - ++ 0.56 0.55 CENPM - - 0.57 0.50
UBE2T - ++ 0.53 0.60 FAM64A - - 0.55 0.58
PHF19 - ++ 0.50 0.50 MND1 - - 0.51 0.55
ZNF367 - ++ 0.52 0.51 FGFR1 - - 0.56 0.53
SNORA72 - ++ 0.43 0.58 HELLS - - 0.58 0.55
KIF23 - + 0.58 0.56 TNFAIP8L1 - - 0.47 0.55
ENAH - + 0.54 0.50 OVOS2 - - 0.40 0.58
MAD2L1 - + 0.40 0.55 ZNF141 - - 0.55 0.52
SMC4 - + 0.54 0.60 LOC100129673 - - 0.39 0.48
SEC31A - + 0.55 0.57 ASPM - - 0.45 0.45
SFPQ - + 0.60 0.49 EPHX4 - - 0.51 0.55
CENPF - + 0.51 0.58 HNRPD - - 0.36 0.55
COBL - - 0.54 0.52 ARPC5L - - 0.59 0.52
PBK - - 0.56 0.56 RGS3 - - 0.57 0.45
MLF1IP - - 0.44 0.58 SIPA1L1 - - 0.55 0.58
SAMHD1 - - 0.60 0.53
aRAR binding site identified within 10 kb of the transcription start site (Hua et al., 2009).
++ RAR binding site detected under high stringency (Hua et al., 2009).
+ RAR binding site detected under low stringency (Hua et al., 2009).
↑ Up-regulated by ATRA (1 μM, 24 h) ≥2-fold.
↓ Down-regulated by ATRA (1 μM, 24 h) ≤50%.
Abbreviations: ER, estrogen receptor; RAR, retinoic acid receptor; ATRA, all trans-retinoic acid; si, small interfering RNA.
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hormone was further confirmed by the observation of
much lower phosphorylation at ser
118 of ER in the hor-
mone depleted cells, when compared with control cells
treated with E2 (Figure 1B).
When hormone depleted MCF-7 cells were seeded at
a low confluency (<20 percent) and grown, in the
absence of hormone and without replenishing the med-
ium, they continued to proliferate and the proliferation
was not inhibited by OH-Tam; we will call this ‘basal’
proliferation. Under these conditions, we have moni-
tored basal proliferation in MCF-7 cells for more than
three months of continuous culture. Treatment with E2
stimulated the cell growth demonstrating that the cells
were hormone-sensitive (Figure 1C). The basal prolifera-
tion was diminished by knocking down ER (Figure 1C).
The expression level of ER mRNA (Figure 1D) progres-
sively decreased with ligand (E2 or OH-Tam) treatment
but the ER protein level (Figure 1E) was stabilized by
the ligands during the treatment period; however, ER
Table 2 Tamoxifen Insensitive genes Repressed by the Apo-ER -> Apo-RARa Axis
Gene ATRA
effect
RAR
a binding
<10 kb
Fold change
siER
Fold change
siRARa1
Gene ATRA
effect
RAR
a binding
<10 kb
Fold change
siER
Fold change
siRARa1
IFI44L ↓ + 1.69 2.22 UBL3 - ++ 1.61 1.58
IFI44 ↓ - 2.09 2.28 SLC7A11 - ++ 1.71 2.03
CCPG1 ↓ - 1.67 1.56 KIAA0652 - ++ 1.57 1.63
SLC25A36 ↓ - 1.66 1.73 PHLDB1 - ++ 1.64 1.55
SETD5 ↓ ++ 1.52 2.11 CCNT2 - - 1.53 1.63
MALL ↓ - 1.67 1.81 STX3 - - 1.52 1.59
LYPD1 ↓ - 1.66 1.59 CLN8 - - 1.71 1.72
FAM186A ↓ - 1.64 1.75 UBXN10 - - 1.73 1.64
GPR158 ↓ - 1.81 1.54 PVR - - 1.63 2.39
CDKN1A ↓ - 1.70 1.51 TNFRSF10A - - 1.54 1.62
CEACAM6 ↑ + 2.35 1.63 FLJ31958 - - 1.71 1.52
LGALS3BP ↑ - 1.98 1.92 C18orf25 - - 1.50 1.61
CTSS ↑ - 1.50 1.86 TAPBP - - 1.62 1.51
SELL ↑ - 1.75 1.71 ADAM17 - - 1.58 1.63
SHROOM1 ↑ - 1.68 1.59 HCP5 - - 1.59 2.52
CP ↑ ++ 1.71 1.75 DISC1 - - 1.80 1.74
ABHD2 ↑ ++ 1.56 1.57 SP100 - - 1.77 1.61
ABLIM1 ↑ ++ 1.56 1.55 AASS - - 1.53 2.17
ALOX5 ↑ - 1.72 2.09 HLA-G - - 1.50 2.33
HLA-C ↑ - 1.51 2.51 HLA-B - - 1.61 2.08
MAP1B ↑ - 2.12 1.51 RSAD2 - - 1.84 3.19
ARHGAP1 ↑ - 1.58 1.55 SGSM3 - - 1.72 1.50
SP110 ↑ - 1.58 1.63 HLA-J - - 1.52 2.04
RTP4 ↑ - 1.60 1.81 SESN1 - - 1.53 1.60
MUC20 ↑ - 1.75 1.91 ANO10 - - 1.51 1.64
RNF38 - + 1.80 1.69 SAMD9 - - 1.68 1.56
C9orf80 - + 1.64 1.53 FLJ13197 - - 1.68 1.57
CEACAM5 - - 2.35 1.70 PGLS - - 1.54 1.81
CNOT4 - - 1.79 1.92 LMO3 - - 1.61 1.58
PLXNA2 - - 1.65 1.86 DNAJC21 - - 1.68 1.61
TTC9 - - 1.76 1.51 SETD2 - - 1.52 2.11
EIF5A2 - - 1.90 1.67 ZNF24 - - 2.10 1.68
FLCN - ++ 1.51 1.53 TTLL11 - - 1.72 1.51
BAZ2A - ++ 1.53 1.58 ZNF544 - - 1.58 1.71
aRAR binding site identified within 10 kb of the transcription start site (Hua et al., 2009).
++ RAR binding site detected under high stringency (Hua et al., 2009).
+ RAR binding site detected under low stringency (Hua et al., 2009).
↑ Up-regulated by ATRA (1 μM, 24 h) ≥2-fold.
↓ Down-regulated by ATRA (1 μM, 24 h) ≤50%.
Abbreviations: ER, estrogen receptor; RAR, retinoic acid receptor; ATRA, all trans-retinoic acid; si, small interfering RNA.
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Figure 1 Hormone-independent effects of ER on the proliferation of hormone-sensitive MCF-7 cells. In all the experiments, MCF-7 cells
were first cultivated in phenol red free DMEM containing 5% charcoal-stripped FBS for 48 hours to deplete hormone. EGR3 mRNA levels in the
cells were measured by real time RT-PCR after a brief (8 h) treatment with vehicle (No ligand), E2 (1 nM) or OH-Tam (100 nM) (A). Cells were also
treated with vehicle (No ligand) or E2 (10 nM) for 30 minutes and ligand-dependent activation of ER was analyzed by western blot using a
specific antibody to detect phosphorylation at ser
118 of ER; GAPDH was probed as a loading control (B). Hormone-depleted MCF-7 cells were
transfected with either ER siRNA or control siRNA and maintained in hormone-depleted conditioned media without further replenishment of the
media. Twenty-four hours after transfection, cells were treated with vehicle (No ligand), E2 (1 nM) or OH-Tam (100 nM); the treatments were
repeated every 48 hours without changing the media. Following the treatment, viable cells were counted daily for six days by the Trypan Blue
dye exclusion assay (C). In parallel, cells were harvested on each day of the treatments and total RNA extracted from them; the mRNA for ER
was measured by real time RT-PCR and the values were normalized to those for GAPDH (D). In addition, cells were harvested in parallel on each
day of the treatments for western blot analysis using antibody to ER; GAPDH was probed in each blot as a loading control (E). P-values for the
differences noted in the text were ≤0.001.
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mRNA (within 24 h) and ER protein (within 48 h) (Fig-
ure 1D and 1E). The results demonstrate a profound
role for apo-ER in supporting basal proliferation in hor-
mone-sensitive MCF-7 cells.
Apo-ER supports MCF-7 cell proliferation by promoting
cell cycle progression
The net proliferation rate of MCF-7 cells under various
conditions indicated in Figure 1 may be determined by
changes in the rates of cell cycling as well as the rates
of cell death. Figure 2A illustrates that during basal pro-
liferation approximately 20% of the cells were in
S-phase. Whereas E2 roughly doubled the proportion of
S-phase cells, OH-Tam (100 nM) did not appreciably
alter the basal cell cycle distribution (Figure 2A). How-
ever, knocking down ER in the hormone-depleted cells
decreased the S-phase cells by approximately 50% (Fig-
ure 2A); the S-phase inhibition was accompanied by an
increase in the proportion of cells in G1 phase indicat-
ing that the ER knockdown inhibited cell proliferation
by inducing cell cycle arrest.
As an alternative method of depleting ER, the hor-
mone depleted MCF-7 cells were treated with fulves-
trant, a well established SERD, which causes proteolytic
degradation of ER. As expected, fulvestrant treatment
resulted in a substantial decrease in ER protein (Figure
3B), without affecting the level of ER mRNA (Figure
3A). Similar to knocking down ER with siRNA, treat-
ment with fulvestrant caused cell cycle arrest (Figure
3C), providing complementary evidence for the role of
apo-ER in supporting cell cycling in hormone depleted
MCF-7 cells.
In contrast to cell cycle distribution the rate of apop-
tosis, measured by staining the cells for Annexin V did
not show a significant change due to ligand treatment
or knocking down ER compared to hormone depletion
(Figure 2B). Fulvestrant treatment modestly increased
the proportion of Annexin V positive cells (from 4.6%
to 8%) (Figure 3D). Therefore, the principal mechanism
by which ER supports basal proliferation of hormone-
sensitive MCF-7 cells is by promoting cell cycle
progression.
Apo-ER supports basal cycling of MCF-7 cells through
regulation of apo-RARa
Among the list of genes whose expression decreased sig-
nificantly upon knocking down ER in MCF-7 cells
depleted of hormone (Additional files 1, 2, 3, 4 and 5),
we observed a decrease in RARa. Since the actions of
antiestrogens and retinoids on breast cancer cells are
profoundly regulated by an ER-RAR axis, it was of inter-
est to examine a possible functional relationship
Figure 2 Hormone-independent effects of ER on cell cycle
phase distribution in hormone-sensitive MCF-7 cells. Hormone-
depleted MCF-7 cells were transfected with either ER siRNA or
control siRNA and maintained in hormone-depleted conditioned
media without further replenishment of the media. Twenty-four
hours after transfection, cells were treated with vehicle (No ligand),
E2 (1 nM) or OH-Tam (100 nM); the treatments were repeated every
48 hours without changing the media. (A) On the indicated days,
the cells as treated above were harvested for flow cytometry
analysis to determine their cell cycle phase distribution. (B) On Day
4 of the above treatment, cells were harvested to measure the
proportion of apoptotic cells by Annexin V staining. P-values for the
differences noted in the text were ≤0.001.
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the context of basal cycling of ER+ breast cancer cells.
In hormone depleted MCF-7 cells, knocking down ER
decreased the level of RARa mRNA by about 40% and
to a greater extent the RARa protein (Figure 4A). How-
ever, the basal ER level was unaltered by knocking down
RARa (Figure 4A). Knocking down either ER or RARa
did not significantly alter the expression of RARs -b and
-g (Figure 4B). The results indicate that apo-RARa is
specifically regulated by apo-ER but not vice versa.
Similar to knocking down ER, knocking down RARa
in hormone-depleted MCF-7 cells decreased the fraction
of S-phase cells (Figure 4C). To test whether the effect
of knocking down ER on the basal cycling of MCF-7
cells could be mediated by apo-RARa, the latter protein
was introduced ectopically at the time of knocking
down ER by co-transfecting an RARa isoform1 expres-
sion plasmid (Figure 4D). Restoring RARa at a level
approaching the original basal level of the protein par-
tially rescued cell cycling (Figure 4D). Similarly, RARa
also partially rescued basal cell cycling in MCF-7 cells
treated with fulvestrant (Figure 4E). On the other hand,
overexpression of RARa1 had no impact on the cell
cycle distribution, indicating that the endogenous level
Figure 3 Effect of fulvestrant on cell cycle phase distribution in hormone-depleted MCF-7 cells. Hormone-depleted MCF-7 cells were
treated with vehicle control or fulvestrant (100 nM) and maintained in hormone-depleted conditioned media without further replenishment of
the media. The treatments were repeated every 48 hours for up to five days. (A) Cells were harvested after three and four days of treatment as
described above and total RNA extracted from them. The mRNA for ER was measured by real time RT-PCR and the values were normalized to
those for GAPDH. (B) Cells were harvested after three and four days of treatment as described above for western blot analysis using antibody to
ER. GAPDH was probed as a loading control. (C) The cells treated as above were harvested on days 3 and 4 for flow cytometry analysis to
determine their cell cycle phase distribution. (D) On Day 4 of the above treatment, cells were harvested to measure the proportion of apoptotic
cells by Annexin V staining. P-values for the differences noted in the text were ≤0.001.
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Page 9 of 17Figure 4 Role of RARa in mediating the hormone-independent effect of ER on basal level cell cycling. (A) Effect of knocking down either
ER or RARa on the mRNA levels (left panel) and protein levels (right panel) of ER and RARa. Cells were transfected with control siRNA, ER siRNA
or RARa siRNA and four days later the cells were harvested to extract total RNA for the measurement of ER and RARa mRNA by real time RT-
PCR; the values were normalized those for GAPDH (control). The cells were also harvested four days after transfection for western blot analysis
using antibody to either ER or RARa; the blots were probed for GAPDH as a loading control. (B) The cells were transfected as described for
Panel A and the cell lysates were probed by western blot using antibodies specific for RARb and RARg; GAPDH was probed as a loading control.
(C) Cells transfected as described in Panel A with control siRNA, ER siRNA and RARa siRNA were analysed by flow cytometry for cell cycle phase
distribution. (D) RARa1 expression plasmid and siRNA against ER were co-transfected into hormone-depleted MCF-7 cells by nucleofection. As
controls, cells were co-transfected with either control siRNA or ER siRNA and the vector plasmid. Cells were harvested three days after
transfection and the cell cycle phase distribution determined by flow cytometry (left panel). The cells were also harvested at the same time for
western blot analysis of the lysates using antibody to ER and RARa (right panel); GAPDH was probed as a loading control. (E) RARa1 expression
plasmid or control vector plasmid was transfected into hormone-depleted MCF-7 cells using Fugene 6. The cells were treated with fulvestrant
(100 nM) or vehicle and harvested after 72 h. The cell cycle phase distribution was determined by flow cytometry. (F) The cells were transfected
as described in Panel E and harvested 96 hours after transfection. The cell cycle phase distribution was determined by flow cytometry (left panel)
and the cell lysates were probed by Western blot using antibody specific for RARa (right panel); GAPDH was probed as a loading control.
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cell cycling (Figure 4F). Taken together, the above
results demonstrate that the ability of apo-ER to support
basal cell proliferation is mediated to a large extent by
its ability to support the expression of the basal level of
apo-RARa.
Apo-ER and apo-RARa support cell cycle in MCF-7 cells
without selectivity with respect to ErbB2 and ErbB3
status
S i n c et h eM C F - 7c e l ll i n ec o m p r i s e sah e t e r o g e n e o u s
population of cells, and since ErbB2 and ErbB3 overex-
pression is associated with resistance to hormonal adju-
vants it was of interest to test whether the ErbB2 and
ErbB3 status of the cells was related to the dependence
of basal cell cycling of MCF-7 cells on apo-ER or apo-
RARa. As expected, treating hormone depleted MCF-7
cells with E2 inhibited ErbB2 and ErbB3 mRNA expres-
sion (Figure 5). Following knockdown of either ER or
RARa, there was not a significant change in the mRNA
levels of ErbB2 and ErbB3 compared to the hormone
depleted control cells (Figure 5). Thus, the regulation of
cell cycling of MCF-7 cells by apo-ER or apo-RARa did
not show an obvious selectivity for a subpopulation of
cells distinguishable by their ErbB2 or ErbB3 status.
MCF-7 cells and several clinical breast tumors express
isoform 1 of RARa
Given the significant differences in structure and regula-
tion between the two RARa isoforms [34] it was of
interest to determine whether only one or both isoforms
were relevant in the regulation of RARa by apo-ER in
breast cancer cells. cDNA prepared from the total RNA
of MCF-7 cells as well as five breast tumors and normal
human tissue controls (breast, spleen, thymus and per-
ipheral blood leukocytes) were analyzed for RARa iso-
form expression by PCR. As seen in Figure 6, whereas
both RARa1a n dR A R a2 were expressed in spleen, thy-
mus and peripheral blood leukocytes, normal breast and
MCF-7 cells as well as four of the five breast tumors
expressed virtually exclusively RARa1( F i g u r e6 ) .T h e
observations made in the limited number of clinical
tumors need to be extended to a larger number of sam-
ples; nevertheless, the observation is consistent with pre-
vious evidence [35] for epigenetic silencing of RARa2
expression in MCF-7 cells and, together with the pre-
ceding observation that RARa1 rescued basal cell
cycling in the ER knockdown cells, indicates that
RARa1 is the relevant receptor isoform in the current
study of breast tumor cells.
Apo-RARa1 mediates regulation by apo-ER of tamoxifen-
insensitive gene complements principally engaged in the
cell division cycle
In contrast to the effect of knocking down ER, the basal
level of RARa1 did not appreciably decrease due to
tamoxifen treatment (Figure 7A); the basal levels of
RARs -b and -g also only decreased by a relatively small
extent due to tamoxifen treatment (Figure 7A). The
gene targets downstream of the apo-ER ® apo-RARa1
pathway were identified by mRNA profiling using Affy-
metrix microarray analysis. Accordingly, data from sepa-
rate ER knockdown and RARa1k n o c k d o w n
experiments in hormone depleted MCF-7 cells were
used to identify overlapping sets of genes that were
either up or down regulated by both ER and RARa1.
The Affymetrix microarray analysis was validated for a
few target genes known to regulate cell proliferation by
real time RT-PCR; they include CDKN1A, MUC20 and
LYPD1, which are negative regulators of cell prolifera-
tion whose basal expression was repressed by apo-ER
Figure 5 ERBB2 and ERBB3 mRNA levels following depletion of
apo-ER or apo-RARa1 in MCF-7 cells. Cells were treated with
vehicle, E2 (1 nM) or transfected with control siRNA, ER siRNA or
RARa siRNA. Ninety-six days later the cells were harvested to extract
total RNA for the measurement of ERBB2 and ERBB3 by real time
RT-PCR. Values are normalized to the GAPDH values. P-values for the
differences noted in the text were ≤0.001.
Figure 6 Identification of major RARa isoforms in various
normal tissues and in breast cancer. Total RNA was extracted
from MCF-7 cells, five human breast tumors and normal tissue
controls (peripheral blood leukocytes, thymus, spleen and breast)
and reverse transcribed into cDNA by RT-PCR. The cDNA fragments
were amplified by competitive PCR using forward primers
specifically against RARa1 and RARa2 and a common reverse
primer. The PCR products were identified by electrophoresis on a
2% agarose gel by ethedium bromide staining. The cDNA for
GAPDH was amplified in each sample as an internal control.
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Figure 7 Tamoxifen-insensitivity of RAR expression and the functional categories of target genes of the apo-ER apo-RARa1a x i s . (A)
Hormone-depleted MCF-7 cells were treated with OH-Tam (100 nM) or vehicle control. Seventy-two hours later, the cell lysates were prepared
and analysed by western blot using antibodies specific for RARa, RARb or RARg; GAPDH was probed as a loading control. The band intensities
are normalized to GAPDH and equalized to a value of 1 for the untreated sample. (B) Real time RT-PCR analysis to confirm the effect of
knocking down either ER or RARa on the mRNA levels of representative target genes found by Affymetrix DNA microarray in this study to be
regulated by apo-ER and apo-RAR in MCF-7 cells: Cells were transfected with control siRNA, ER siRNA or RARa siRNA and four days later the cells
were harvested to extract total RNA for the measurement of the relevant mRNAs; the values were normalized those for GAPDH (control). The P-
values for the differences noted in the text were <0.001. (C) and (D) mRNA profiling was performed to identify common target genes of apo-ER
and apo-RARa1 in MCF-7 cells. Apo-ER and apo-RARa1 were knocked down separately in hormone-depleted MCF-7 cells. Seventy-two hours
after transfection with the appropriate siRNA, total mRNA was extracted and mRNA profiling was carried out using Affymetrixs microarray
analysis. P-values for the differences noted in the text were ≤0.001.
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proliferation whose basal expression was supported by
apo-ER and RARa1 (Figure 7B).
Table 1 lists the common target genes of apo-ER and
apo-RARa1 whose basal expression was supported by
both apo-ER and apo-RARa1 in a tamoxifen-insensitive
manner; these genes were identified based on a decrease
in basal mRNA level by at least 40% due to transfection
of cells with siRNA specific for either ER or RARa1. Of
the 53 annotated genes that were identified in this man-
ner, gene ontology analysis (DAVID Bioinformatics
Resources 2008) [36,37] revealed genes known to sup-
port the cell division cycle and mitosis as the predomi-
nant functional category (Figure 7C); the gene sets
included additional functional categories that support
proliferation (Figure 7C).
Table 2 lists the common target genes of apo-ER and
apo-RARa1 whose basal expression was decreased by
apo-ER or apo-RARa1 in a tamoxifen-insensitive man-
ner; these genes were identified based on an increase in
basal mRNA level by at least 50 percent due to transfec-
tion of cells with siRNA specific for either ER or
RARa1. Of the 68 annotated genes that were identified
in this manner, gene ontology analysis (DAVID Bioin-
formatics Resources 2008) revealed several categories of
genes (Figure 7D); however, among genes functionally
related to proliferation, there was enrichment for those
that are known to negatively regulate cell proliferation
(Figure 7D) in contrast to the genes activated by apo-
ER/apo-RARa1 noted above.
The common gene targets of apo-ER and apo-RARa1 are
generally insensitive to ATRA but are enriched in RAR
binding sites in associated chromatin regions
In the classical mechanism of the transcriptional activity
of class II nuclear receptors, including RAR, the apo-
protein is in a repressive association with the target
gene and the binding of agonist to the receptor results
in gene activation due to a co-regulator switch [38].
However, Affymetrix microarray analysis of MCF-7 cells
following treatment with ATRA (1 μM, 24 h) indicated
that only a fraction of the genes regulated by apo-ER/
apo-RARa1 were regulated by ATRA (Tables 1 and 2).
Specifically, among the 53 genes whose basal expression
was supported by apo-ER/apo-RARa1, 6 genes were
inhibited by ATRA to <50 percent and 1 was activated
>2-fold (Table 1). On the other hand, among the 68
genes whose basal expression was repressed by apo-ER/
apo-RARa1, 15 genes were activated by ATRA >2-fold
and 10 genes were inhibited to <50 percent. Notably,
none of the ATRA regulated genes in Tables 1 and 2
are functionally associated with the cell division cycle.
Since putative RAR binding sites have been globally
mapped in the chromatin of MCF-7 cells [39], we used
this information to identify the presence of RAR binding
sites associated with the apo-ER/apo-RARa1t a r g e t
g e n e sl i s t e di nT a b l e s1a n d2 .A si n d i c a t e di nt h e
T a b l e s ,1 8o ft h e5 3g e n e si nT a b l e1a n d1 4o ft h e6 8
genes in Table 2 were associated with RAR binding sites
within a distance of 10 kb of the transcription start
sites. The genes in Table 1 had significant enrichment
(Hypergeometric test) for RAR binding sites within 10
kb with P = 0.03. The enrichment for RAR binding sites
for the genes in Table 2 had a P-value of 0.19. Thus,
despite the low frequency with which the apo-ER/apo-
RARa1 target genes are regulated by ATRA, there is a
significant enrichment among them for associated RAR
binding sites, largely among gene targets that are insen-
sitive to ATRA.
Down-regulation of RARa1 inhibits hormone-independent
cell cycle progression in other breast cancer cell lines
Since down-regulating, rather than activating RARa1
may be an attractive therapeutic strategy in concert with
estrogen ablation in breast cancer, it was of interest to
test the effect of depleting RARa1 in other model cell
lines. Similar to MCF7 cells, RARa1b u tn o tR A R a2
was expressed in the estrogen-sensitive T47 D and ZR-
75-1 cell lines as determined by competitive RT-PCR
(Figure 8A). Interestingly, in contrast to MCF-7 cells,
RARa1 was not regulated by apo-ER and further knock-
ing down apo-ER did not affect cell cycling (data not
shown). Thus, the regulation of RARa1b ya p o - E Ri s
somehow disrupted in these cells; this finding further
supports the conclusion that regulation of RARa1
underlies the effect of apo-ER on cell cycling. Neverthe-
less, in either cell line, knocking down RARa1( F i g u r e
8B showing RARa1m R N Aa n d8 Cs h o w i n gR A R a1
protein) inhibited cell cycle progression in the absence
of hormone (Figure 8D), similar to MCF7 cells. The
results demonstrate a consistent role for RARa1i ns u p -
porting a basal level cycling in hormone depleted breast
cancer cells.
Discussion
ER is known to regulate genes in a ligand-independent
manner [40,41]. Hormone-independent actions of ER
play an important role in supporting the growth of hor-
mone-refractory breast tumors [12]. On the other hand,
studies of gene regulation by ER in estrogen-sensitive
breast cancer cells have mostly focused on estrogen-
responsive genes that have profound roles in tumor
growth and development and the effects of tamoxifen
on gene regulation by estrogen [42]. The findings of this
study, however, highlight a potentially significant
mechanism of hormone-independent transcriptional
action of ER in hormone-sensitive breast cancer cells.
This action of ER is clearly a major contributor to the
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Page 13 of 17ability of hormone-sensitive breast cancer cells to main-
tain a basal level of proliferation under conditions of
hormone-depletion. This effect of apo-ER occurred pri-
marily through supporting the cell division cycle.
Remarkably, the action of apo-ER was also rather insen-
sitive to tamoxifen at a dose that is clinically relevant to
circulating concentrations of the drug that induce all of
the surrogate biomarkers of clinical response [43,44].
Similar to clinical breast tumors, breast cancer cell lines
are heterogeneous and can yield clonal populations of
inherently tamoxifen resistant cells that are variably ER-
dependent [45]; nevertheless, the fraction of S-phase
cells in hormone-depleted or tamoxifen-treated cells
under the in vitro conditions in this study was much
higher than the frequency of emergence of aggressively
growing colonies in tamoxifen-treated cultures [45].
Therefore, it is likely that the basal level of S-phase cells
observed in hormone-depleted or tamoxifen treated cul-
tures represent a substantial proportion of cells in which
the cell cycle progression is slowed. In a tumor environ-
ment, however, this slow proliferation must be offset by
cell death, resulting in an overall tumoristatic effect.
Since a basal level of cell division is an essential pre-
condition for progressive events leading to the eventual
development of resistance of breast tumors to hormonal
adjuvant therapy, understanding the mechanism of the
hormone-independent effects of ER in hormone-sensi-
tive cells is important.
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Figure 8 Effect of depleting RARa1 on cell cycle phase distribution of hormone-depleted T47 D and ZR-75-1 cells. (A) Total RNA was
extracted from T47 D and ZR-75-1 cells and normal tissue controls (peripheral blood leukocytes, thymus and spleen) and reverse transcribed
into cDNA by RT-PCR. The cDNA fragments were amplified by competitive PCR using forward primers specifically against RARa1 and RARa2 and
a common reverse primer. The PCR products were identified as previously described (Figure 5). The cDNA for GAPDH was amplified in each
sample as an internal control. In B and C, cells were transfected with control siRNA or RARa siRNA and 72 hours later the cells were harvested
to extract total RNA or to prepare cell lysates. In B, the mRNA for RARa1 was measured by real time RT-PCR and the values were normalized
those for GAPDH (control). In C, the cells lysates were analyzed by western blot using antibody to RARa; the blots were probed for GAPDH as a
loading control. (D) Seventy-two hours after transfection with control siRNA or RARa siRNA, T47 D and ZR-75-1 cells were harvested for flow
cytometry analysis to determine their cell cycle phase distribution. P-values for the differences noted in the text were ≤0.001.
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established ER-RAR axis has been best characterized in
the context of ligand effects (estrogen, retinoids, tamoxi-
fen + retinoids) [20,46]. The results of this study how-
ever establish that in hormone-sensitive cells that are
depleted of hormone or treated with tamoxifen, a major
mechanism by which ER supports the cell cycle is by
supporting the basal expression of RARa1 .T h er o l eo f
RARa1 in mediating the action of apo-ER is strongly
evident from the following observations: (i) In hormone-
depleted cells, apo-ER maintained the basal expression
level of RARa1 but was not itself regulated by RARa1;
(ii) The regulation of RARa1 by apo-ER was insensitive
to tamoxifen; (iii) Knocking down RARa1 negatively
impacted the basal cell cycle progression and restoring
basal apo-RARa1 levels rescued basal level cell division
following depletion of ER; (iv) Apo-RARa1 indepen-
dently regulated a complement of genes in a manner
that strongly favored cell division similar to their regula-
tion by apo-ER. This mechanism was remarkable for the
following reasons. First, apo-ER regulated the a1s u b -
type of RAR but not RARs -b or - g. Second, most of
the common target genes of apo-ER and apo-RARa1
including all of the genes involved in the cell division
cycle were insensitive to ATRA. These findings suggest
that a major molecular mechanism by which apo-ER
supports basal cell division in hormone-sensitive breast
cancer cells may not be sensitive to conventional RAR
ligands (agonists), but would be predictably opposed by
specific inactivators or down-regulators of RARa1.
The cell cycle regulation, which occurs through the
apo-ER/apo-RARa1 axis, could theoretically exclude a
subpopulation(s) of cells; such a subpopulation(s) could
represent tumor cells that are either inherently resistant
to hormonal adjuvants or that undergo progressive
changes leading to resistance. Whereas the findings in
this study do not preclude this possibility, we found no
evidence for residual cycling cells following depletion of
apo-ER or apo-RARa1 that were characterized by ErbB2
or ErbB3 overexpression, common features associated
with a resistant phenotype [47,48].
It is well established that the RARa gene is activated
by estrogen; however, there is evidence in the literature
that ER associates at a basal level with the core promo-
ter of the RARa gene by tethering to DNA bound Sp1
[49]. Apo-ER may thus directly regulate the RARa gene
to maintain the basal expression level of RARa1. The
observation that the RARa1 protein level decreased
more dramatically than its mRNA upon knocking down
ER suggests that apo-ER also regulates RARa1b ya d d i -
tional posttranscriptional mechanisms.
The results of this study further indicate that multiple
molecular mechanisms must underlie the downstream
action of apo-RARa1 on target genes in the context of
mediating the effects of apo-ER. The apo-ER/apo-
RARa1 axis regulates genes in both a positive and a
negative manner to support cell division; both sets of
target genes were enriched for associated chromatin
sites of RAR binding, suggesting that RARa1m u s ta c t
on these target genes by direct as well as indirect
mechanisms. RAR belongs to the Class II subfamily of
nuclear receptors, which typically, in their ligand-free
(apoprotein) form, maintain a transcriptionally repressed
state of target genes activated by the corresponding ago-
nists [38]. However, only a small fraction of genes regu-
lated by the apo-ER-RARa1 axis appeared to be
regulated by this classical mechanism of action of
RARa1, since (i) the genes repressed by apo-RARa1
were largely insensitive to ATRA and (ii) most genes
activated by apo-RARa1 were ATRA-insensitive. There-
fore, apo-RARa1 must act by non-classical mechanisms
on most of the target genes, including those with asso-
ciated RAR binding sites.
RARa is consistently present in the nucleus in breast
tumors and its expression levels correlate with that of
the proliferation marker, ki-67 [50]. The functional
RARa isoform in different hormone-sensitive breast
cancer cell lines and that identified in a limited number
of breast tumors was almost exclusively of type 1, an
isoform that is believed to be genetically redundant [51].
The findings reported here would predict that agents
that selectively target the a1s u b t y p eo fR A Rf o rf u n c -
tional inhibition or degradation would significantly
enhance hormone ablation therapy in breast cancer
since this would further decrease cycling cells. Since the
effect of depleting RARa1 occurs through a different
gene regulatory program compared with retinoid ago-
nists, and since RARa1 is genetically redundant and
could be the major or only RARa subtype in breast can-
cer cells, this new approach (rather than the use of RAR
agonists) to enhancing hormonal adjuvant therapy in
breast cancer may be clinically more acceptable. The
structural divergence of the two RARa isoforms arising
from alternative promoter usage and alternative splicing
includes differences in functional sub-domains [34]
which may enable their differential targeting with phar-
macological agents. This approach may have fewer side
effects than SERDs due to a redundancy of RAR sub-
types in other tissues. Studies are underway to test this
concept in pre-clinical models of hormone-sensitive
breast cancer.
Conclusions
We have observed that in hormone-sensitive breast
cancer cells, there is a hormone-independent compo-
nent through which ER supportsp r o l i f e r a t i o na n dt h a t
apo-RARa1i sam a j o rm e d i a t o ro ft h i se f f e c t .T h ed a t a
also show that the majority of genes regulated by
Salazar et al. Breast Cancer Research 2011, 13:R18
http://breast-cancer-research.com/content/13/1/R18
Page 15 of 17apo-RARa1 do not confirm to the classical model of
gene regulation by Class II nuclear receptors since they
are not regulated by ATRA. Further, selectively down-
regulating RARa1 might significantly enhance hormone
ablation therapy in breast cancer since this would
further decrease cycling cells. Since the effect of deplet-
ing RARa1 occurs through a different gene regulatory
p r o g r a mc o m p a r e dw i t hr e t i n o i da g o n i s t s ,a n ds i n c e
RARa1 is genetically redundant and appears to be the
only RARa subtype in breast tumor cell lines and possi-
bly the major subtype in clinical tumors, this new
approach (rather than the use of RAR agonists) to
enhancing hormonal adjuvant therapy in breast cancer
may be clinically more acceptable. RARa1i sa l s os t r u c -
turally divergent from RARa2, which is expressed in
normal tissues, so that it should be possible to develop
selective down-regulators of RARa1.
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